PEAK6’s Kymera Therapeutics KYMR Stock Holding History

PEAK6’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,500	Closed	-$302K	–	3325
2024 Q4	$302K	Buy	+7,500	New	+$339K	﹤0.01%	2388

Other funds holding KYMR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PEAK6's KYMR Position: Q1 2025 in Review

PEAK6 sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 7,500 shares — an estimated $302K sold.

PEAK6 first reported a position in KYMR in Q4 2024 and held it in 1 quarter. The position peaked at $302K in Q4 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

PEAK6 reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 7,500 Kymera Therapeutics shares in Q1 2025, an estimated $302K.
PEAK6 first reported a position in Kymera Therapeutics in Q4 2024 and held it in 1 quarter.
PEAK6's Kymera Therapeutics position peaked at $302K in Q4 2024.
173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.